Release Date: December 5, 2017
Expiration date: June 5, 2018
Estimated Time to Complete Activity: 1.0 hour 
                                           

CME ACCREDITATION AND DESIGNATION

The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for participants in exchange for completed activity evaluations.

 

CME for MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

OVERVIEW

Platelets play an important role in the pathophysiology of acute coronary syndrome and thrombotic complications of percutaneous coronary intervention. Pretreatment with oral agents has limitations due to challenges with timing and absorption. The use of IIb/IIIa receptor inhibitors has been shown to improve patient outcome with ACS. Patients with STEMI and large thrombus may benefit from the use of GPIs during PCI. The goal of this program is to review the optimal antiplatelet treatments for patients requiring anticoagulation. Attendees benefit from a comprehensive review of the latest guidelines and information to give them evidence-based approaches for avoiding bleeding in patients undergoing PCI. Attendees will also gain a better understanding of the latest data.

 

AGENDA

The Usage of Small Molecule GP IIB/IIIA Inhibitors in ACS Patients: An Evidence and Guideline-Based Approach
Molly Szerlip

Bleeding Avoidance Strategies With Small Molecule IIB/IIIA Inhibitors
Adhir Shroff

Moderated Case Presentation: High-Risk Large Thrombus ACS Patient Undergoing PCI
Tayo A. Addo

Moderated Case Presentation: Inadequately Pretreated ACS Patient for PCI
Thomas M. Tu

Moderated Case Presentation: Small Molecule IIB/IIIA Inhibitors as a Preferred Option for STEMI PCI
Thomas D. Stuckey

Moderated Case Presentation: Tailored Patient: Rising Co-Morbidities in the PCI Patient
Amit Amin

LEARNING OBJECTIVES

By the end of this program, participants should be able to:

1) Discuss the differences between the use of oral and IV anticoagulation therapy.

2) Identify patients that have been inadequately pretreated for PCI and the optimal treatment.

3) Review the available GIIb/IIIa small molecule inhibitors available.

TARGET AUDIENCE

This activity is designed for interventional cardiologists, cardiac surgeons, clinical cardiologists, vascular medicine specialists, and other healthcare professionals.

ACTIVITY EVALUATION

Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.

DISCLOSURE STATEMENT

It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.

Discussion of off-label product usage and/or off-label product use is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.

Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty not complying with this policy are not permitted to participate in this activity.

FACULTY DISCLOSURE SUMMARY

KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E) Equity (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit

Tayo A. Addo: Nothing to Disclose

Amit Amin: (G/R) Volcano Corporation (C/H/S) Terumo Medical Corporation, The Medicines Company, AstraZeneca

Adhir Shroff: (C/H/S) CSI

Thomas D. Stuckey: Nothing to Disclose

Molly Szerlip: (C/H/S) Abbott Vascular, Edwards Lifesciences, Medtronic

Thomas M. Tu: Nothing to Disclose

 

Planning Committee

Robert Blanco (Planner)
(S) Cardiovascular Research Foundation

ACTIVITY SPONSORSHIP AND SUPPORT

This program is sponsored by the Cardiovascular Research Foundation. It is supported through educational grants from Medicure Pharma and was developed without influence from commercial supporters. 

HOW TO RECEIVE CME CREDIT

To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Robert Blanco at rblanco@crf.org .